RT Journal Article
SR Electronic
A1 Hitt Nichols, Emma
T1 Idarucizumab Reverses Dabigatran in Elderly or Renally Impaired
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 14
OP 15
DO 10.1177/1559897714568633
UL http://mdc.sagepub.com/content/14/55/14.abstract
AB In elderly or renally impaired volunteers, the antibody fragment idarucizumab rapidly and completely reversed the anticoagulation effect of dabigatran, sustained for at least 24 hours. Re-administration of dabigatran after 24 hours resulted in anticoagulation similar to that observed during initial treatment. There were no clinically relevant drug-related events; infusion-related effects were similar between arms.